The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

• Main Authors: Cleo Goyvaerts, Karine Breckpot
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2018-09-01
• Series: Frontiers in Immunology
• Subjects: viral vaccine; dendritic cell; T cell; cancer; immunotherapy; preclinical and clinical
• Online Access: https://www.frontiersin.org/article/10.3389/fimmu.2018.02052/full

Dendritic cells (DCs) are recognized as highly potent antigen-presenting cells that are able to stimulate cytotoxic T lymphocyte (CTL) responses with antitumor activity. Consequently, DCs have been explored as cellular vaccines in cancer immunotherapy. To that end, DCs are modified with tumor antigens to enable presentation of antigen-derived peptides to CTLs. In this review we discuss the use of viral vectors for in situ modification of DCs, focusing on their clinical applications as anticancer vaccines. Among the viral vectors discussed are those derived from viruses belonging to the families of the Poxviridae, Adenoviridae, Retroviridae, Togaviridae, Paramyxoviridae, and Rhabdoviridae. We will further shed light on how the combination of viral vector-based vaccination with T-cell supporting strategies will bring this strategy to the next level.